Seeking Alpha

Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the...

Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the potential blockbuster Btk inhibitor. The stock's a blockbuster itself, up nearly 60% since hitting a 52-week low in early March.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|